The special issue of PharmacoEconomics pertaining to developing nations was a welcome move, with authors discussing various themes relating to pharmaceutical economics. The topics discussed included cost-effectiveness analyses and the future of health technology assessment (HTA) in healthcare decisionmaking in the greater Asia region. However, papers in this special issue did not provide an ans...

like many other developing countries pharmacoeconomics and outcome research and its applications in national health system is a new but promising filed in iran. although decision makers of iran national health system decided to use pharmacoeconomics in the decision making approach several hurdles including lack of reliable national data, lack of expertise and local experience are the main chall...

Cost-effectiveness analysis (CEA) represents the most important tool in the health economics literature to quantify and qualify the reasoning behind the optimal decision process in terms of the allocation of resources to a given health intervention. However, the practical application of CEA in the regulatory process is often limited by some critical barriers, and decisions in clinical practice ...

This article is devoted to pharmacoeconomics and patients’ compliance the therapy of iron deficiency anemia. These directions are relatively young in science their importance often remains underestimated by most specialists. Pharmacoeconomics’ main goal determine optimal medicine for treating disease’s cost-effectiveness ratio. Therefore, this review presents facts that therapeutic efficacy spe...

Background: Pharmacoeconomics is receiving increasing attention globally as a set of tools ensuring efficient use of resources in health systems, albeit with different applications depending on the contextual, cultural and development stages of each country. The factors guiding design, implementation and optimisation of pharmacoeconomics as a steering tool under the universal health coverage pa...